Influence of Specific Collagen Peptides on Recovery After Exercise Induced Muscle Damage
Influence of Specific Collagen Peptides on Parameters of Biomechanical and Systemic Recovery After Exercise-induced Muscle Damage
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1150
- University of Vienna, Institute of Sport Science
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- No subjective symptoms during physical exertion
- Stable weight and dietary behaviour
- Body Mass Index (BMI) between 18.5 and 24.9
- No extensive strength/endurance sports so far (less than 3 h/week)
- No complaints during strenuous physical activity
Exclusion Criteria:
- Circumstances that impair/prevent sporting activity (e.g. chronic heart disease, arrhythmia, heart valve disease, arthritis etc.)
- Intolerance/aversion to animal protein
- Arterial hypertension (high blood pressure) (syst > 200 mmHg and/or diast > 105 mmHg) at rest
- Presence of insulin-dependent diabetes mellitus
- Liver and/or kidney disease that precludes a high protein load
- Collagen supplementation or regular intake of other dietary supplements in the last 6 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Collagen
15g of collagen peptides ingested daily
|
Participants ingest 15 grams of either specific collagen peptides or Placebo daily
Both arms undergo a 12-week trainingintervention 3x/week
|
|
Placebo Comparator: Placebo
15g of Placebo ingested daily
|
Both arms undergo a 12-week trainingintervention 3x/week
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in maximal voluntary contraction (MVC)
Time Frame: Baseline (pre, post, 24 hours, 48 hours) and after 12 weeks (pre, post, 24 hours, 48 hours)
|
Measured by isokinetic dynamometer
|
Baseline (pre, post, 24 hours, 48 hours) and after 12 weeks (pre, post, 24 hours, 48 hours)
|
|
Change in rate of force development (RFD)
Time Frame: Baseline (pre, post, 24 hours, 48 hours) and after 12 weeks (pre, post, 24 hours, 48 hours)
|
Measured by isokinetic dynamometer
|
Baseline (pre, post, 24 hours, 48 hours) and after 12 weeks (pre, post, 24 hours, 48 hours)
|
|
Change in countermovement jump height (CMJ)
Time Frame: Baseline (pre, post, 24 hours, 48 hours) and after 12 weeks (pre, post, 24 hours, 48 hours)
|
Measured by force plate
|
Baseline (pre, post, 24 hours, 48 hours) and after 12 weeks (pre, post, 24 hours, 48 hours)
|
|
Change in subjective pain score
Time Frame: Baseline (pre, post, 24 hours, 48 hours) and after 12 weeks (pre, post, 24 hours, 48 hours)
|
Measured by visual analogue scale
|
Baseline (pre, post, 24 hours, 48 hours) and after 12 weeks (pre, post, 24 hours, 48 hours)
|
|
Change in Achilles tendon cross-sectional area
Time Frame: Baseline and after 12 weeks
|
Measured by ultrasound
|
Baseline and after 12 weeks
|
|
Change in Vastus Lateralis fibre length
Time Frame: Baseline (pre, post, 24 hours, 48 hours) and after 12 weeks (pre, post, 24 hours, 48 hours)
|
Measured by ultrasound
|
Baseline (pre, post, 24 hours, 48 hours) and after 12 weeks (pre, post, 24 hours, 48 hours)
|
|
Change in collagen related blood markers
Time Frame: Baseline (pre, post, 2 hours, 24 hours, 48 hours) and after 12 weeks (pre, post, 2 hours, 24 hours, 48 hours)
|
Measured by blood analysis
|
Baseline (pre, post, 2 hours, 24 hours, 48 hours) and after 12 weeks (pre, post, 2 hours, 24 hours, 48 hours)
|
|
Change in Achilles tendon echo intensity
Time Frame: Baseline and after 12 weeks
|
Measured by ultrasound
|
Baseline and after 12 weeks
|
|
Change in Vastus Lateralis echo intensity
Time Frame: Baseline and after 12 weeks
|
Measured by ultrasound
|
Baseline and after 12 weeks
|
|
Change in body composition parameters (fat mass, fat-free mass, extracellular mass, body cell mass)
Time Frame: Baseline and after 12 weeks
|
Measured by bioelectrical impedance analysis
|
Baseline and after 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Daniel Koenig, Prof. Dr., University of Vienna, Institute of Sport Science
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 00765
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.